indazoles has been researched along with Carcinoma, Papillary in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| García-Alemán, J; Mancha-Doblas, I; Molina-Vega, M; Sebastián-Ochoa, A; Tinahones-Madueño, F; Trigo-Pérez, JM | 1 |
| Abd Elmageed, ZY; Abdel-Mageed, AB; Kandil, E; Li, X; Ma, J; Mondal, D; Slakey, D; Tsumagari, K | 1 |
| Bono, P; Joensuu, H; Peltola, K; Rautiola, J; Utriainen, T | 1 |
| Bible, KC; Bossou, AR; Cradic, KW; Grebe, SK; Isham, CR; Milosevic, D; Netzel, BC | 1 |
| Agate, L; Boucher, A; Bycott, P; Chen, C; Cohen, EE; Ingrosso, A; Jarzab, B; Kane, MA; Kim, S; Licitra, L; Locati, LD; Ou, SH; Pithavala, YK; Qin, S; Wirth, LJ | 1 |
| Egawa, S; Endo, K; Hatano, T; Ishii, G; Kimura, T; Seki, K; Yamada, H | 1 |
| Carcangiu, ML; Cohen, EE; Greco, A; Joseph, L; Khattri, A; Licitra, L; Lingen, MW; Locati, LD; Nagilla, M; Pelosi, G; Reddy, P; Schechter, RB; Seiwert, TY; Watson, S | 1 |
| Brabant, G; Burrows, N; Eustace, A; Fitzmaurice, RJ; Hoang-Vu, C; Irlam, J; Resch, J; Rowling, EJ; Telfer, BA; Valentine, HR; West, CM; Williams, J; Williams, KJ | 1 |
| Moretti, S; Puxeddu, E; Romagnoli, S; Voce, P | 1 |
| Ambrogi, F; Ciottoli, GB; Giannotti, P | 1 |
1 review(s) available for indazoles and Carcinoma, Papillary
| Article | Year |
|---|---|
Targeted molecular therapies in thyroid carcinoma.
Topics: Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Medullary; Carcinoma, Papillary; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thyroid Neoplasms | 2009 |
3 trial(s) available for indazoles and Carcinoma, Papillary
| Article | Year |
|---|---|
Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Papillary; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Salvage Therapy; Sulfonamides; Sunitinib; Survival Rate; Treatment Failure | 2014 |
Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Papillary; Diarrhea; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quality of Life; Thyroid Neoplasms; Treatment Outcome | 2014 |
Lonidamine plus adriamycin versus adriamycin alone in the adjuvant treatment of recurrent papillary carcinomas of the urinary bladder.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Doxorubicin; Eye; Female; Heart; Humans; Indazoles; Male; Middle Aged; Pyrazoles; Urinary Bladder Neoplasms | 1984 |
6 other study(ies) available for indazoles and Carcinoma, Papillary
| Article | Year |
|---|---|
Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer: experience in clinical practice.
Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; Axitinib; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Survival Rate; Thyroid Neoplasms; Treatment Outcome | 2018 |
Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Carcinoma; Carcinoma, Papillary; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Humans; Indazoles; Mitogen-Activated Protein Kinase Kinases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Sulfonamides; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2013 |
Development and characterization of a differentiated thyroid cancer cell line resistant to VEGFR-targeted kinase inhibitors.
Topics: Animals; Carcinoma; Carcinoma, Papillary; Cell Culture Techniques; Cell Line, Tumor; DNA Mutational Analysis; Drug Resistance, Neoplasm; Humans; Indazoles; Mice; Molecular Targeted Therapy; Neoplasm Invasiveness; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrimidines; ras Proteins; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Thyroid Cancer, Papillary; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2014 |
[A case of papillary renal cell carcinoma type 2 resistant to sunitinib responded to second line therapy with axitinib].
Topics: Axitinib; Carcinoma, Papillary; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Humans; Imidazoles; Indazoles; Male; Middle Aged; Protein Kinase Inhibitors | 2014 |
Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Papillary; Class I Phosphatidylinositol 3-Kinases; DNA Copy Number Variations; DNA Mutational Analysis; Drug Screening Assays, Antitumor; Female; Gene Amplification; Genetic Association Studies; Humans; Imidazoles; Indazoles; Iodine Radioisotopes; Male; Middle Aged; Phosphatidylinositol 3-Kinases; Polymorphism, Single Nucleotide; Radiation Tolerance; Radiopharmaceuticals; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2015 |
Phosphatidylinositide 3-kinase (PI3K) and PI3K-related kinase (PIKK) activity contributes to radioresistance in thyroid carcinomas.
Topics: Animals; Carcinoma; Carcinoma, Papillary; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; DNA Damage; DNA-Binding Proteins; Dose-Response Relationship, Radiation; Enzyme Activation; Female; Histones; Humans; Hypoxia; Indazoles; Mice; Mice, Nude; Neoplasm Transplantation; Oxygen; Phosphatidylinositol 3-Kinases; Radiation Tolerance; Signal Transduction; Sulfonamides; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2016 |